IMR Press / EJGO / Volume 40 / Issue 3 / DOI: 10.12892/ejgo4736.2019
Open Access Original Research
Tumor response to concurrent chemoradiotherapy depending on PIK3CA gene mutational status among Azerbaijanian cervical cancer patients
Show Less
1 National Centre of Oncology, Baku, Azerbaijan
Eur. J. Gynaecol. Oncol. 2019, 40(3), 443–446; https://doi.org/10.12892/ejgo4736.2019
Published: 10 June 2019
Abstract

Background: The aim of this research was to study PIK3CA mutation depending tumor response to concurrent chemoradiotherapy among Azerbaijanian cervical cancer patients. Materials and Methods: The authors investigated treatment results of 136 Stage IB-IVA cervical cancer patients. Treatment consisted of external beam radiotherapy, weekly cisplatin, and high-dose rate brachytherapy. PIK3CA gene mutations were detected using PIK3CA mutation analysis kit. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed. Results: The authors revealed activation of PIK3CA gene in 49 (36%) patients in total. PIK3CA mutations were found in five (10.2%) cases of adenocarcinomas and in 44 (89.8%) patients with squamous cell cervical cancer. Of the 136 patients retrieved in this study, 112 (82,3%) patients had complete response, 23 (18,7%) had partial response, and only one had progression of the disease. The frequency of compete response was significantly lower in PIK3CA mutation positive patients (77.6% vs. 92%, p = 0,035). Conclusion: The authors revealed some association between PIK3CA gene alterations and tumor response after chemoradiotherapy in patients with locally advanced cervical cancer. More than one-third of cervical cancer patients are PIK3CA gene mutations carriers and in the future potentially could benefit from newly discovered therapeutic agents which directly target PIK3CA.

Keywords
Cervical carcinoma
Tumor response
PIK3CA gene
Chemoradiotherapy
Share
Back to top